CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM CDH17 clinical trial, a CAR T-cell therapy built on research
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Same organ, different disease Words matter in cancer, especially when the name of an organ becomes
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Why do some neuroendocrine tumors grow slowly for years, while others progress more quickly? Researchers have
We recently spoke with John Metzcar, PhD, president of AMEND USA, neuroendocrine cancer patient and bioinformatics researcher. Can you share a little bit about yourself
By Anna Greene, PhD, Chief Scientific Officer, Neuroendocrine Tumor Research Foundation At NETRF, we often talk about the importance of funding foundational science. These studies
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Clinical trial news in neuroendocrine cancer is moving quickly. In this roundup, we highlight recent developments
NETRF BOSA Leadership Transition The Neuroendocrine Tumor Research Foundation is pleased to share updates on the leadership and membership of its Board of Scientific Advisors
By Anna C. Greene, PhD | NETRF Chief Scientific Officer In May, I attended the 2026 Small Cell Lung Cancer Consortium hosted by the National
By Udhayvir Singh Grewal, MD GI/Neuroendocrine Medical Oncologist and Assistant Professor of Medical Oncology, Winship Cancer Institute of Emory University School of Medicine Dr. Grewal contributed
By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we fund research that can change how neuroendocrine cancers